Skip to main content

Lipocine Inc.

LPCN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001535955

No open-market purchases or sales by Lipocine Inc. insiders were filed in the last 90 days; 36 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.

Holders of 5% or more of LPCN

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lipocine Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of LPCN
HolderLatest formStakeChangeFirst filedLatest filingFiling
Squadron Capital Management LLC13G/A9.50%530.0K shares+0.50 ppfrom 9.00%Dec 23, 20252 filingsFeb 17, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

2 Schedule 13D and 13G filings on Lipocine Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on LPCN
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 17, 202611:49 AM ETSquadron Capital Management LLCand 3 others13G/A9.50%530.0K shares+0.50 ppfrom 9.00%Dec 31, 2025SEC
Dec 23, 20253:49 PM ETSquadron Capital Management LLCand 3 others13G9.00%500.0K sharesNewDec 18, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Lipocine Inc. shares.

No Form 144 notices for Lipocine Inc. are on file.